HER2-positive breast cancer
ASCO Meeting: Enhertu + Perjeta Potential First-Line Combo for Metastatic Breast Cancer
Trastuzumab deruxtecan combined with Perjeta may become first-line therapy for people with metastatic HER2-positive ...
JUNE 16, 2025
Tucatinib Plus T-DM1 Improves PFS in Metastatic Breast Cancer
Adding tucatinib (Tukysa, Seagen) to trastuzumab emtansine (Kadcyla, T-DM1, Genentech) improved progression-free ...
FEBRUARY 19, 2024
FDA Approves Margenza to Treat HER2-Positive Breast Cancer
The FDA approved margetuximab-cmkb (Margenza, MacroGenics) in combination with chemotherapy for the treatment of ...
DECEMBER 22, 2020
New TKI May be a Game Changer for Breast Cancer
Advances in therapy have improved overall survival for patients with HER2-positive metastatic breast cancer, but ...
AUGUST 26, 2020
FDA Approves Phesgo for HER2-Positive Breast Cancer
The FDA granted approval to Genentech’s Phesgo, a fixed-dose combination of pertuzumab and trastuzumab with ...
JULY 1, 2020
Tukysa Approved in Combination With Chemo for Nonresectable HER2+ Breast Cancer
The FDA approved the tyrosine kinase inhibitor tucatinib (Tukysa, Seattle Genetics) in combination with ...
APRIL 23, 2020
Nerlynx Granted Expanded Indication for Advanced/Metastatic HER2+ Breast Cancer
The FDA approved neratinib (Nerlynx, Puma) in combination with capecitabine for adults with advanced or metastatic ...
FEBRUARY 27, 2020
Enhertu: New Option for Previously Treated Unresectable or Metastatic HER2+ Breast Ca
The FDA granted accelerated approval to fam-trastuzumab deruxtecan-nxki (Enhertu, Daiichi Sankyo) for the treatment ...
JANUARY 7, 2020
Neratinib + Capecitabine Has Potential for HER2+ Breast Cancer Brain Mets
Neratinib plus capecitabine is an active combination for HER2-positive breast cancer metastatic to the CNS, ...
SEPTEMBER 27, 2017
Nerlynx Approved for HER2+ Breast Cancer
The FDA has approved neratinib for extended adjuvant therapy in early-stage HER2-positive breast cancer.
JULY 17, 2017
How I Manage Adjuvant Therapy in HER2-Positive Breast Cancer
Adjuvant anti-HER2 therapy in combination with chemotherapy has markedly improved disease-free survival and overall ...
JULY 12, 2017
Pertuzumab Plus Trastuzumab Yields Small Benefit at Steep Price
Adding pertuzumab to trastuzumab for women with HER2-positive breast cancer reduced the risk for invasive breast ...
JUNE 1, 2017